p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α–mediated down-regulation of CXCL12
Kensuke Kojima(Kōchi University), Michael Andreeff(The University of Texas MD Anderson Cancer Center), Marina Konopleva(Albert Einstein College of Medicine), Naoki Shinojima, Teresa McQueen(Leukemia Research Foundation), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Ye Chen(Anhui Medical University), Elizabeth J. Shpall(Scripps MD Anderson Cancer Center), Rodrigo Jácamo
Cited by 105
Related Papers
An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis.
|PubMed|2013|1.6k
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
|Nature Genetics|2019|627